ANI Pharmaceuticals is building a leading Rare Disease company focused on Serving Patients, Improving Lives

RECENT NEWS

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

2026-07-16

READ MORE >

ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis

2026-07-13

READ MORE >

NASDAQ - ANIP

$79.32

-2.6 (-3.17%)

Pricing delayed by 20 minutes
Last updated 2026-07-17 15:26:00